在三个登革热流行国家越南、泰国和哥伦比亚使用Dengvaxia和一种未来候选疫苗的登革热疫苗接种策略的多国研究
本研究基于9岁儿童血清阳性率数据,用个体水平元种群传播模型评估CYD-TDV和一种假设新疫苗在越南、泰国和哥伦比亚的接种影响与成本效果。两种疫苗在2000美元/DALY阈值下均可能具有成本效果。CYD-TDV最经济策略为常规接种9岁儿童加10-29岁一次性补种;新疫苗在越南和泰国最经济策略分别为接种9-29岁和9-18岁,哥伦比亚为接种1-5岁低龄儿童。
要点
- CYD-TDV和假设新疫苗在2000美元/DALY阈值下均可能具有成本效果,取决于接种成本。
- CYD-TDV在三国最经济策略均为常规接种9岁儿童加10-29岁一次性补种。
- 新疫苗最经济策略在越南为接种9-29岁,泰国为9-18岁,哥伦比亚为1-5岁。
核心结论
- CYD-TDV和假设新疫苗在2000美元/DALY阈值下均可能具有成本效果,取决于接种成本。
- CYD-TDV在三国最经济策略为常规接种9岁儿童加10-29岁一次性补种。
- 新疫苗最经济策略在越南为接种9-29岁,泰国为9-18岁,哥伦比亚为接种1-5岁。
研究设计与样本
- 基于9岁儿童实际血清阳性率拟合个体水平元种群传播模型,模型曾用于WHO-SAGE工作组。
- 应用各国参数值估算残疾调整生命年,比较两种疫苗四种干预策略联合常规和补种活动的成本效果。
- 研究国家为越南、泰国和哥伦比亚三个登革热流行国家。
主要发现
- CYD-TDV和假设新疫苗在2000美元/DALY阈值下均可能具有成本效果,取决于接种成本。
- CYD-TDV最经济策略为常规接种9岁儿童加10-29岁一次性补种,三国一致。
- 新疫苗最经济策略在越南为接种9-29岁,泰国为9-18岁,哥伦比亚为接种1-5岁。
关键数值与推荐
- 成本效果阈值:2000美元/DALY。
- CYD-TDV最经济策略:常规接种9岁儿童加10-29岁一次性补种。
- 新疫苗最经济策略:越南接种9-29岁,泰国接种9-18岁,哥伦比亚接种1-5岁。
临床怎么用
- 研究结果可帮助决策者了解将CYD-TDV或未来登革热疫苗纳入预算受限的国家免疫规划时的预期影响和成本效果。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The dengue vaccination era began when Dengvaxia (CYD-TDV) became available in 2016. In addition, several second-generation vaccine candidates are currently in phase 3 trials, suggesting that a broader availability of dengue vaccines may be possible in the near future. Advancing on the recent WHO-SAGE recommendations for the safe and effective use of CYD-TDV at the regional level on average, this study investigates the vaccination impacts and cost-effectiveness of CYD-TDV and of a hypothetical new vaccine candidate (NVC) in a country-specific manner for three endemic countries: Vietnam, Thailand, and Colombia. METHODS: The vaccination impacts of CYD-TDV and NVC were derived by fitting the empirical seroprevalence rates of 9 year olds into an individual-based meta-population transmission model, previously used for the WHO-SAGE working group. The disability-adjusted life years were estimated by applying country-specific parametric values. The cost-effectiveness analyses of four intervention strategies in combination with routine and catch-up campaigns were compared for both vaccines to inform decision makers regarding the most suitable immunization program in each of the three countries. RESULTS AND CONCLUSION: Both CYD-TDV and NVC could be cost-effective at the DALY threshold cost of $2000 depending upon vaccination costs. With CYD-TDV, targeting 9 year olds in routine vaccination programs and 10-29 year olds as a one-off catch-up campaign was the most cost-effective strategy in all three countries. With NVC, while the most cost-effective strategy was to vaccinate 9-29 and 9-18 year olds in Vietnam and Thailand respectively, vaccinating younger age cohorts between 1 and 5 years old in Colombia was more cost-effective than other strategies. Given that three countries will soon face decisions regarding whether and how to incorporate CYD-TDV or future dengue vaccines into their budget-constrained national immunization programs, the current study outcomes can be used to help decision makers understand the expected impacts and cost-effectiveness of such vaccines.
引用
- Lee JS, Lourenço J, Gupta S, et al. A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia. Vaccine. 2018. PMID: 29573874. doi:10.1016/j.vaccine.2018.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。